Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease

Lancet

Volumn 365, Issue 9454, 2005, Pages 167-175

  Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; ANTIINFLAMMATORY AGENT; AROFYLLINE; BAY 19 8004; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; C 3885; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOMILAST; CORTICOSTEROID; DIGOXIN; DRUG METABOLITE; ELB 353; ERYTHROMYCIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; N OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; RECEPTOR SUBTYPE; ROFLUMILAST; ROLIPRAM; SALBUTAMOL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; HEADACHE; HUMAN; LUNG FUNCTION; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

EID: 11844267183     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)17708-3     Document Type: Review

References (52)

1. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 58:(suppl 1):2003;1-83
2. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: National Clinical Guideline on Management of Chronic obstructive disease in adults in primary and secondary care. Thorax. 59:(suppl 1):2004;1-232
3. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 340:1999;1948-1953
4. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 320:2000;1297-1303
5. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function on chronic obstructive pulmonary disease. N Engl J Med. 343:2000;1902-1909
6. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol. 107:2001;461-468
7. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 105:2000;1123-1129
8. Malmstrom K, Rodriguez-Gomez G, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Ann Intern Med. 130:1999;487-495
9. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 167:2003;813-818
10. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 157:1998;351-370
11. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs. 63:2003;2575-2594
12. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 47:2000;127-162
13. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol. 108:2001;671-680
14. Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal. 9:1997;227-236
15. Torphy TJ, Barnette MS, Underwood DC, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther. 12:1999;131-135
16. Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell functionby subtype selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Clin Pharmacol; 128: 1393-98.
17. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 297:2001;267-279
18. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 297:2001;280-290
19. Wollin N, Bundschuh DS, Ostermann A, et al. Inhibition of asthma key mediators and inflammation by roflumilast: effects on the time course in ovalbumin challenged brown Norway rats. Am J Respir Crit Care Med 2004; 169: A803 (abstr).
20. Boswell-Smith V, Spina D, Page CP. Regulation by selective phosphodiesterase 4 isoenzyme inhibitor of non-adrenergic, non cholinergic contract on guinea pig isolated main bronchus. Am J Respir Crit Care Med 2004; 169: A180 (abstr).
21. Zussman BD, Benincosa LJ, Webber DM, et al. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers. J Clin Pharmacol. 41:2001;950-958
22. Zussman BD, Davie CC, Kelly J, et al. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast. Pharmacotherapy. 21:2001;653-660
23. Zussman BD, Kelly J, Murdoch RD, Clark DJ, Schubert C, Collie H. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. Clin Ther. 23:2001;921-931
24. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. Pharmacotherapy. 35:2001;1535-1539
25. Kelly J, Murdoch RD, Clark DJ, Zussman B, Davie C, Howland K. Smoking status has no effect on the clearance of a single dose of Arilflo (SP207499)(15mg), an orally active, novel, second generation PDE4 inhibitor in healthy male volunteers. Am J Respir Crit Care Med 1999; 159: A807 (abstr).
26. Hauns B, Huennemeyer A, Coch M, Manegold A, Zech K, Bethke TD. Lack of pharmacokinetic interaction between roflumilast and erythromycin. Am J Respir Crit Care Med 2004; 169: A612 (abstr).
27. Hauns B, Huennemeyer A, Duursema L, et al. Lack of pharmacokinetic interaction between roflumilast and concomitant warfarin treatment. Am J Respir Crit Care Med 2004; 169: A612 (abstr).
28. Manegold A, Hauns B, David M, Zech K, Bethke T, Wurst W. Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500mcg to 1000mcg are dose linear in healthy subjects. Eur Respir J 2002; 20 (suppl 38): 108S (abstr).
29. Drollmann A, Hünnemeyer A, Hartmann M, et al. Pharmacokinetic characteristics of roflumilast and its active metabolite roflumilast-N-oxide are not infected by food intake. Eur Respir J 2002; 20 (suppl 38): 109S (abstr).
30. Drollmann A, Hartmann M, Zech K, et al. Patients with severe renal impairment do not require dose adjustment of roflumilast. Eur Respir J 2002; 20 (suppl 38): 108S (abstr).
31. Weimar C, Bethke T, Westphal K, Zech K, Siegmund W, Wurst W. Roflumilast and its active metabolite, roflumilast-N-oxide do not interact with inhaled salbutamol. Am J Respir Crit Care Med 2002; 165: A594 (abstr).
32. Hünnemeyer A, Bethke M, David M, Westphal K, Siegmund W, Wurst W. No interaction of roflumilast and its active metabolite, roflumilast-N-oxide with inhaled budesonide. Am J Respir Crit Care Med 2002; 165: A595 (abstr).
33. van Schalkwyk EM, van Heerden K, Bredenbröker D, et al. Dose dependent inhibitory effect of roflumilast, new orally active, selective phosphodiesterase 4 inhibitor on allergen induced early and late asthmatic reaction. Eur Respir J 2002; 20 (suppl 38): 110S (abstr).
34. Nell H, Louw C, Leichtl S, Rathgeb F, Neuhäser M, Baden PG. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. Am J Respir Crit Care Med 2000; 161: A200 (abstr).
35. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol. 42:2002;297-303
36. Nieman RB, Fisher BD, Amit O, Dochorn RG. SB207499 (Ariflo, a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1998; 157: A413 (abstr).
37. Compton CH, Cedar E, Nieman RB, Amit O, Langley SJ, Sapene M. Ariflo improves pulmonary function in patients with asthma: results of a study in patients taking inhaled corticosteroids. Am J Respir Crit Care Med 1999; 159: A522 (abstr).
38. Compton CH, Duggan M, Cedar E, et al. Ariflo efficacy in a 12 month study of patients with asthma. Am J Respir Crit Care Med 2000; 161: A505 (abstr).
39. Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, Rathgeb F, Wurst W. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor is effective in the treatment of asthma. Eur Respir J 2002; 20 (suppl 38): 303S (abstr).
40. Izquierdo JL, Bateman ED. Villasante C, Schmid-Wurlitsch C, Bredenbröker D, Wurst W. Long term efficacy and safety over one year of once daily roflumilast, a new orally active selective phosphodiesterase 4 inhibitor in asthma. Am J Respir Crit Care Med 2003; 167: A765 (abstr).
41. Aubier M, Sauer R, Boszormenyi G, Albrecht A, Bredenbröker D, Bethke TD. Roflumilast a novel selective PDE4 inhibitor shows early onset of efficacy in asthma. Am J Respir Crit Care Med 2004; 169: A322 (abstr).
42. Albrecht A, Leichtl S, Bredenbröker D, Bethke T, Wurst W. A new orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone propionate in asthma control. Eur Respir J 2002; 20 (suppl 38): 304S (abstr).
43. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet. 358:2001;265-270
44. Eddleston JD, Compton CH, Neiman R, et al. Cilomilast (Ariflo), a potent selective phosphodiesterase 4 inhibitor reduces exacerbations in COPD patients: results of a six month trial. Am J Respir Crit Care Med 2001; 163: A771 (abstr).
45. Eddleston JD, Compton CH, Nieman R, et al. Cilomilast (Ariflo) a potent selective inhibitor of phosphodiesterase 4 improves lung functions in patients with COPD: results of a six month trial. Am J Respir Crit Care Med 2001; 163: A277 (abstr).
46. Borker R, Spencer M, Knobil K, Zhu J, Jhingran P. Combining probablistic uncertainty analysis with non-parametric bootstrap procedure to establish the non-drug cost effectiveness of cilomilast in COPD. Am J Respir Crit Care Med 2004; 169: A328 (abstr).
47. Compton CH, Eddleston JD, Cedar E, et al. Cilomilast (Ariflo), 15mg bid safety in a 6 month clinical trial programme. Am J Respir Crit Care Med 2001; 163: A909 (abstr).
48. Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 168:2003;976-982
49. Bredenbröker D, Syed J, Leichtl S, Rathgeb F, Wurst W. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease. Eur Respir J 2002; 20 (suppl 38): 374S (abstr).
50. Rabe KF, Chapman KR, Jubert J, Vetter N, Witte S, Bredenbroeker D. Roflumilast, a novel selective phosphodiesterase 4 inhibitor improves lung function in patients with moderate to severe COPD. Am J Respir Crit Care Med 2004; 169: A518 (abstr).
51. O'Donnell D, Muir JS, Jenkins C, et al. Roflumilast, a novel selective phosphodiesterase 4 inhibitor improves quality of life and lowers exacerbation rates in patients with moderate to severe COPD. Am J Respir Crit Care Med 2004; 169: A602 (abstr).
52. Bateman ED, Holmes M, Muir JS, Andrae K, Witte S, Bredenbroeker D. Safety profile of roflumilast, a novel selective phosphodiesterase 4 inhibitor in patients with moderate to severe COPD. Am J Respir Crit Care Med 2004; 169: A596 (abstr).